AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06311318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower eyelid massage
Description: The massage technique was executed with the patient in a fully open-eyed state, maintaining an upward gaze. The lateral aspect of the distal phalanx of the index finger was employed, exerting pressure on the lower eyelid to bring its margin into contact with the upper eyelid margin for a duration of 10 seconds per repetition. This procedure comprised 10 repetitions per set, administered once hourly, spanning 10 hours daily. The massage instruction was provided either by the authors or plastic surgery residents.
Study NCT04040491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
Study NCT04040491 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
Study NCT01724619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] fluorinated dihydrotestosterone (FDHT)
Study NCT01489241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
Study NCT03746288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAN008
Description: CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
Study NCT03746288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN008
Description: CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
Study NCT00514852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose and Glycerin based artificial tear
Description: 1 to 2 drops into each eye as needed but at least twice daily
Study NCT00514852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose
Description: 1 to 2 drops into each eye as needed but at least twice daily
Study NCT02581150 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of Occlusive Arterial Disease
Description: Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
Study NCT02086032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg 17 beta-estradiol
Description: Comparing sleeping quality between micronized progesterone and dydrogesterone users.
Study NCT02086032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: Comparing sleeping quality between micronised progesterone and dydrogesterone users.
Study NCT02086032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Description: Comparing sleeping quality between micronised progesterone and dydrogesterone users
Study NCT03316911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MKit
Description: MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
Study NCT01875679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Surgical Coaching
Study NCT01875679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgical Training
Description: Surgical training as per participant's residency program
Study NCT04635605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
Study NCT04635605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test
Description: Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
Study NCT05449015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% atropine
Description: Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
Study NCT05449015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% atropine
Description: Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
Study NCT00959400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal
Description: Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
Study NCT04704362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ensuring Quality in Psychological Support
Description: Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
Study NCT04704362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Training and Supervision
Description: Trainees are trained using a manual for non-specialist-delivered psychological interventions.
Study NCT00684047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS Grifols
Description: Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
Study NCT00684047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS Grifols
Description: Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
Study NCT00684047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Compression
Description: Manual Compression. Primary Part (II)
Study NCT00448396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study NCT03073746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Search
Study NCT03073746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Search
Study NCT00699179 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
Study NCT04139122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0132
Description: SJP-0132 is administered as an eye drop
Study NCT03657771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DED
Description: DED: Diet eliminating dairy
Study NCT03657771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FREE
Description: FREE: Diet eliminating dairy and food additives
Study NCT03355469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Exercise + Metformin
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
Study NCT03355469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Exercise + Metformin
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
Study NCT03355469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Intensity Exercise + Placebo
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
Study NCT03355469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Exercise + Placebo
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
Study NCT02836509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
Study NCT02836509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Study NCT02965768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone HCl
Description: 4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
Study NCT02965768 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone HCl
Description: 4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
Study NCT03340103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LUTEIN ofta 0,5 gocce
Description: LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
Study NCT03340103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
Study NCT04139122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as an eye drop
Study NCT02872220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y65 110 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study NCT02872220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y51 002 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study NCT02872220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 V27 104 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study NCT02872220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride [NaCl]
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Study NCT02817477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Delivered intranasally using an atomizer
Study NCT02817477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Delivered either as an IM injection or a slow IV bolus
Study NCT01245088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chondroitin sulfate
Description: 400 mg orally three times daily for 8 weeks
Study NCT01607203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl Daily
Description: Decapeptyl 0.2 mg SC once 1day
Study NCT01607203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnyl
Description: 5000 IU SC
Study NCT03849391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skate group
Description: This group takes 500 mg/day Skate Skin extract for 12 weeks
Study NCT03849391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes 500 mg/day Placebo for 12 weeks
Study NCT01853488 — intervention group
Intervention type: RADIATION
Intervention: DXA
Description: Osteodensitometry
Study NCT01853488 — intervention group
Intervention type: RADIATION
Intervention: pQCT
Description: Osteodensitometry
Study NCT00936689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective TACE via microsphere loaded with Doxorubicin
Description: Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
Study NCT00936689 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Selective traditional TACE
Description: Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
Study NCT03567317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Description: Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
Study NCT00910299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
Study NCT00910299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg oral daily maintenance dose up to 6 months.
Study NCT02395172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
Study NCT02395172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
Study NCT01911910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic coaching plus standard care
Description: The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
Study NCT05037435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)
Description: Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
Study NCT05037435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
Study NCT03704636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00028
Description: Noninvasive pulse oximeter sensor
Study NCT00313781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
Study NCT00313781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Study NCT00849667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farletuzumab
Description: Farletuzumab IV infusion.
Study NCT00849667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion.
Study NCT00849667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion.
Study NCT00849667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.
Study NCT00849667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taxane
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.
Study NCT00849667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Farletuzumab-matched placebo
Description: Farletuzumab-matched placebo IV infusion.
Study NCT01629407 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
Study NCT02451787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2400 units per day for 3 months
Study NCT02451787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 2400 units per day for 3 months
Study NCT01334398 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health & Wellness
Description: The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment.
Study NCT03153839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic physical activity in babies
Description: A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again.
Study NCT03981159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training for three months, twice per week (60 minutes per session).
Study NCT02492633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
Study NCT02492633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
Study NCT02492633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~1. A web-based smoking cessation intervention via Facebook~2. Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~3. A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program.
Study NCT03026348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer
Study NCT00313781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone is administered at a dose of 5 mg twice daily.